Singapore's ASLAN Licenses Gastric Cancer Compound From Array; Will Bring To POC And Find Partner

Singapore's ASLAN Pharmaceuticals Pte Ltd. has inked a licensing deal with Colorado-based Array BioPharma Inc. to develop Array's oral HER2/EGFR inhibitor ARRY-543, currently entering Phase II for solid tumors

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip